Free Trial
CVE:TLT

Theralase Technologies (TLT) Stock Price, News & Analysis

Theralase Technologies logo
C$0.26
0.00 (0.00%)
(As of 11/4/2024 05:20 PM ET)

About Theralase Technologies Stock (CVE:TLT)

Key Stats

Today's Range
C$0.26
C$0.28
50-Day Range
C$0.17
C$0.38
52-Week Range
C$0.14
C$0.38
Volume
117,111 shs
Average Volume
121,739 shs
Market Capitalization
C$63.84 million
P/E Ratio
N/A
Dividend Yield
1,115.38%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II clinical trial for the treatment of Bacillus Calmette Guérin - Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ. Further, its product candidates include TLC-2000, a superpulsed and visible red laser technology that accelerates healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure limit for tissue, as well as related accessories. Additionally, it researches, develops, manufactures, and distributes controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100 to healthcare practitioners primarily for the healing of pain. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine; and the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. The company is based in Toronto, Canada.

Receive TLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theralase Technologies and its competitors with MarketBeat's FREE daily newsletter.

TLT Stock News Headlines

Theralase Technologies Inc. (TLT.V)
This company will win the AI race
Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.
Theralase Technologies, Inc.: Theralase Extends Warrants
See More Headlines

TLT Stock Analysis - Frequently Asked Questions

Theralase Technologies' stock was trading at C$0.18 at the beginning of the year. Since then, TLT stock has increased by 48.6% and is now trading at C$0.26.
View the best growth stocks for 2024 here
.

Theralase Technologies Inc. (CVE:TLT) posted its earnings results on Monday, August, 12th. The company reported ($0.01) EPS for the quarter. The company earned $0.10 million during the quarter.

Shares of TLT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Theralase Technologies investors own include Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), Alphabet (GOOG), Netflix (NFLX), Advanced Micro Devices (AMD) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
8/12/2024
Today
11/04/2024
Next Earnings (Estimated)
12/04/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Devices
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
20
Year Founded
N/A

Profitability

Net Income
C$-4,410,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$1.04 million
Cash Flow
C$0.01 per share
Book Value
C$0.01 per share

Miscellaneous

Free Float
N/A
Market Cap
C$63.84 million
Optionable
Not Optionable
Beta
1.36
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

This page (CVE:TLT) was last updated on 11/5/2024 by MarketBeat.com Staff
From Our Partners